Policy Guideline

Evidenced-Based Opioid Prescribing Recommendations Following Hand and Upper-Extremity Surgery

Alexander J. Adams, MD, * Asif M. Ilyas, MD, MBA *, 1

* Department of Orthopedic Surgery, Rothman Institute at Thomas Jefferson University, Philadelphia, PA
1 Rothman Opioid Foundation, Philadelphia, PA

The United States’ opioid epidemic has taken an immense toll over the past 2 decades when assessed by morbidities, mortalities, and economic costs. Prescription opioids are a substantial contribution to this public health emergency, and it is critical for health care providers to practice good analgesic stewardship. Interventions have effectively curtailed opioid overuse, including prescription drug monitoring programs, educational initiatives, and multimodal analgesia strategies. Surgeons, particularly hand surgeons or those who perform musculoskeletal procedures, have been implicated as high-volume opioid prescribers. Guidelines for appropriate opioid dosing and analgesic management strategies after common hand and upper-extremity surgeries are sparse and offer an area for meaningful improvement. We sought to generate comprehensive, evidence-based recommendations for postoperative analgesia regimens for common hand and upper-extremity procedures.

The scope of the United States’ opioid epidemic is staggering. From 1999 to 2019, approximately 500,000 people have died from an opioid-related overdose. Drug overdose deaths in the United States increased in 2019 to 70,630 people, with >70% involving an opioid, translating to 136 daily deaths from opioid overdose. Prescription opioids were involved in >28% of all opioid overdose deaths in 2019, totaling >14,000 deaths or 38 deaths daily. From an economic standpoint, prescription opioid abuse, dependence, and overdose cost the US economy an estimated US $78.5 billion annually. Although Americans represent <5% of the global population, they consume 80% of the global oral opioid supply.

Measures have been enacted to curb opioid overprescription, including prescription drug monitoring programs, provider education on opioid prescribing, and multimodal analgesia strategies. These initiatives have resulted in an overall 19% decrease in annual US opioid prescribing rates from 2006 to 2017 and a 7% decrease in prescription opioid-involved US death rates from 2018 to 2019. Despite these advances, the total opioid amounts prescribed per person in morphine milligram equivalents (MMEs) are still >3 times higher than those prescribed in 1999. In 2019, 10.1 million people misused prescription opioids. In 2017, >17% of Americans had at least 1 opioid prescription filled, with a mean of 3.4 opioid prescriptions dispensed per patient, at an average dose of 45.3 MME per day over 18 days. Recent studies also reported an increase in opioid-related overdoses since the rise of the recent coronavirus disease 2019 pandemic, attributed to stresses on social and health care safety nets.

Hand and upper-extremity surgeons are generally high-volume surgeons who routinely prescribe opioids after surgery. Opioid abuse and dependence increased 152% in hand surgery patients between 2002 and 2011. Beyond the greater societal consequences, excessive opioid use directly affects the hand surgeon’s daily practice. Farley et al showed that preoperative opioid use was associated with poorer surgical outcomes and greater complication and revision rates in thumb carpometacarpal (CMC) arthroplasty and arthroscopic rotator cuff repair. Opioid misuse has been associated with increased overall morbidity (odds ratio, 2.3) and mortality (odds ratio, 3.7) after elective hand surgery.

Complications in other organ systems have been cited in hand surgery patients, including respiratory failure, surgical site infection, pneumonia, myocardial infarction, hyperalgesia, and gastrointestinal events.
Several studies have shown that larger initial prescriptions were associated with a higher postoperative opioid usage in common procedures, including cubital tunnel release, trigger finger release, thumb CMC arthroplasty, and carpal tunnel release. Yeung et al. showed that hand surgery patients retained unused postoperative opioids in 78% of cases, which may lead to diversion and abuse. Fortunately, there has been a trend toward reducing opioid overprescription by upper-extremity surgeons. Education has been implicated as a critical factor in reducing opioid overprescription after hand surgery.

Stepan et al. instituted a mandatory 1-hour opioid education program for their hand and upper-extremity surgeons. They demonstrated a 52.3% reduction in the mean total MME prescribed, and the adherence to guidelines improved after dissemination up to 9–11 months later. Stanek et al. distributed an index card containing prescription guidelines for 4 common procedures to all hand surgery providers. They demonstrated a reduction in the mean postoperative prescription size ranging from 15% to 48% and less variability among prescription patterns. Rhode Island passed the state legislature in 2016 that capped daily MMEs that providers can prescribe to opioid-naive patients. Six months after passing this legislation, there was a 30% decrease in total MMEs in the 30-day postoperative period after thumb CMC arthroplasty and distal radius fracture fixation. However, clinical outcomes were not examined. In summary, it is paramount for hand surgeons to improve opioid prescribing through opioid stewardship and education while still meeting their patients’ analgesia requirements.

Problem Statement

After common hand and upper-extremity surgeries, inadvertent postoperative opioid prescribing can lead to dependency, abuse, diversion, death, and poor surgical and nonsurgical treatment outcomes; however, guidelines for appropriate opioid dosing and analgesic strategies are lacking.

Proposed Solution

Comprehensive, evidence-based recommendations for postoperative analgesia regimens for common hand and upper-extremity procedures, based on published evidence in hand surgery and overall medical/surgical literature.

Future Direction and Long-Term Focus

Pain management can vary based on the individual circumstances. Analgesic principles are typically divided into acute, postoperative, chronic, and palliative pain management. For this review, pain management principles refer to acute and postoperative pain and will be presented using the current best evidence and defining principles. The defining principles for postoperative analgesia regimens are outlined in the following section; detailed, evidence-based recommendations are presented later.

1. Nonpharmacologic treatment strategies should be used whenever possible.
2. Multimodal nonopioid analgesics should be considered as the first-line pain management prescription and are best prescribed as standing, rather than as needed (PRN), regimen.
3. Opioids should be provided for breakthrough pain PRN at the lowest dose, duration, and quantity feasible.
4. Risk factors for opioid abuse should be considered before prescribing an opioid.

5. Opioid use education should be delivered before surgery or when providing an opioid prescription.

Nonpharmacologic treatment strategies should be incorporated whenever possible. These strategies include but are not limited to rest, ice, elevation, and compressive surgical dressings that are secure but not constrictive.

Nonopioid analgesics should be considered as the first-line pharmacologic treatment for pain and the foundational agent in a multimodal pain management strategy. Moreover, nonopioid analgesics are best used on standing rather than on a PRN basis. Specifically, acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) have shown great effectiveness in multimodal analgesia studies. Multimodal regimens have a unique potential to target multiple pain pathways, unlike opioids alone, and they are further detailed below. However, opioid–acetaminophen combination medications (ie, Percocet, Roxicet, Vicodin, etc) should be avoided to prevent accidental overdosing on acetaminophen.

Risk factors for opioid abuse and dependence should be considered before providing opioid prescriptions. These include substance abuse history, psychiatric conditions, and low educational level.

If an opioid is prescribed, the lowest dose and shortest duration possible should be performed with the patient. Counseling has decreased voluntary opioid use while maintaining high pain management satisfaction. Counseling should establish the duration of therapy and goals of opioid use (2 weeks postoperative is recommended, with a maximum duration of 6 weeks) and may include the use of a physician–patient opioid agreement. Also, patients should be advised on the safe storage of prescribed opioids to avoid diversion and abuse.

Ilyas et al. randomized 237 patients undergoing outpatient hand surgeries to receive preoperative education or not. Patients receiving education consumed significantly fewer opioids (<0.05) and still had similar daily visual analog scale scores.

Counseling consisted of a short video presentation on a tablet before surgery, a paper handout, and a face-to-face discussion with the surgeon. Vincent et al. similarly randomized 131 patients undergoing upper-extremity surgery to receive preoperative counseling. They found that counseling resulted in a significant decrease in opioid consumption after surgery despite no difference in reported pain levels (P = .007). Counseling consisted of a short video presentation on a tablet before surgery, a paper handout, and a face-to-face discussion with the surgeon. Zohar-Bondar et al. showed similar results in their study of patients receiving counseling before outpatient soft tissue hand procedures.

If an opioid is prescribed, the lowest dose and shortest duration possible should be prescribed. The Centers for Disease Control and Prevention recommends a maximum of 50 MMEs (approximately 6 doses of 5 mg of oxycodone) for no more than 3–7 days in most acute musculoskeletal injuries. Tramadol may be considered a first-line opioid agent because it may be equally efficacious as other stronger opioids with a lower risk of dependency. Tramadol is a schedule IV drug by the Drug Enforcement Administration compared with schedule II traditional opioids, similar to morphine, codeine, oxycodone, and hydrocodone, which have a higher risk of...
dependence and dangerous side effects. Compared with traditional opioids, tramadol has a lower affinity for opioid receptors and causes mild reuptake inhibition of norepinephrine and serotonin.\textsuperscript{44} However, medication interactions with tramadol must be considered on an individual basis, and risks of its use still exist, including but not limited to dependence and rarely serotonin syndrome. Analgesia regimens should be individualized to the specific procedure at hand; for example, carpal tunnel release will require less analgesia than elbow fracture repair.

Surgeon prescribers should engage other providers on the patient’s health care delivery team during the perioperative period (ie, primary care provider or pain management specialist). This communication can avoid double-prescription and discrepancies in prescription assumptions.\textsuperscript{30} If patients with an opioid use history proceed to surgery, baseline opioid prescription doses should be continued. They may require dose increases by 1.5–2 times in the acute postoperative period (2 weeks).\textsuperscript{10,40} For these patients, postoperative analgesia is best managed by their pain management provider preferentially, if applicable. Finally, these guidelines are based on the current evidence on postoperative analgesia in hand and upper-extremity surgery. Future studies should examine opioid-free multimodal regimens, nerve block alternatives, other anti-inflammatory agents and nonnarcotics, and the role of sleep and patient psychology on postoperative pain.

**Current Evidence for Oral Nonopioid Analgesics**

1. Nonsteroidal anti-inflammatory drugs

Multiple regimens have been presented for common hand and upper-extremity procedures, including naproxen 220 mg twice a day for 14 days, and ibuprofen 800 mg every 8 hours for 3 days, scheduled then as PRN.\textsuperscript{30,40} Insufficient evidence exists to recommend against NSAIDs for bone healing when used for <14 days.

Standard precautions and contraindications of NSAIDs should be considered, and pharmacy or medical specialists should be consulted for assistance in unclear cases. Nonsteroidal anti-inflammatory drugs should be used with caution in patients with renal insufficiency, cardiovascular disease, gastrointestinal bleeding, and anticoagulation/antiplatelet therapy. A concomitant proton pump inhibitor can be used, such as omeprazole 20 mg twice a day or pantoprazole 40 mg daily. This is recommended in high-risk patients aged >50 years and/or patients with gastric ulcer risk factors while taking NSAIDs as recommended by the American College of Gastroenterology.\textsuperscript{46}

2. Acetaminophen

Multiple regimens have been presented for common hand and upper-extremity procedures, including acetaminophen 650 mg twice a day or every 6 hours or 1,000 mg every 8 hours for 14 days.\textsuperscript{40} The US Food and Drug Administration recommends maximum of 4,000 mg daily for <10 days in healthy adults with normal liver function, no other acetaminophen sources, and <2 alcoholic drinks daily. Recently, manufacturers such as McNeil’s “Tylenol” have recommended 3,000–3,250 mg daily because of reports of overdoses in patients taking standard doses up to 4,000 mg daily.\textsuperscript{40} However, these reports have been because of patients unintentionally ingesting acetaminophen through other sources (sleep medications, cough medications, etc). Patients with abnormal liver function tests, active hepatitis, cirrhosis, or another active hepatic disease should consider a daily maximum dose of ≤2,000 mg daily. Standard precautions and contraindications should be considered, and pharmacy or medical specialists should be consulted for assistance in unclear cases.

3. Neuralgia-related Drugs

Anticonvulsant regimens have been less commonly reported in the hand surgery literature. However, they have been reported to be effective in nerve repair surgery and historically more painful procedures such as olecranon open reduction internal fixation and basal joint arthroplasty.\textsuperscript{40} Regimens include desmopressin (intravenous 0.5 mcg/kg over 20 minutes at the start of surgery) for nerve repair and gabapentin 300 mg twice or thrice a day for 3 weeks after surgery.\textsuperscript{40,40} Zollinger et al\textsuperscript{47} proposed via in a randomized controlled trial that 500 mg of vitamin C taken daily by patients with distal radius fractures resulted in an absolute risk reduction of 15% of developing complex regional pain syndrome, to which many institutions have adhered.\textsuperscript{30,40} However, more recent studies have challenged the effectiveness of prophylactic vitamin C against chronic regional pain syndrome.\textsuperscript{48,49} Therefore, there is insufficient evidence to justify recommending the use of vitamin C. However, given its low cost and lack of side effects, its use has few drawbacks.

**Current Evidence for Postoperative Opioid Requirements**

The published literature from hand and upper-extremity surgery publications and other relevant sources provides valuable data to develop evidence-based opioid prescribing recommendations. Tables 1 to 4 provide the breakdown of the current best evidence on patient-reported opioid requirements after common soft tissue hand/wrist, soft tissue elbow/forearm, bony hand/wrist, and bony elbow/forearm procedures, respectively. A broad synthesis of this literature can be summarized accordingly:

1. Opioids are overprescribed after hand and upper-extremity surgery at 2 or 3 times above actual consumption.\textsuperscript{52} Greater initial prescriptions are associated with higher postoperative opioid usage in hand surgery.\textsuperscript{23–25}

2. Opioid use after most soft tissue hand surgeries is <5 opioid tablets, and even 0 when nonopioid analgesics are recommended.\textsuperscript{5,7,33–41}

3. Opioid use after bony surgeries is higher than that for soft tissue surgeries.\textsuperscript{5,7,34} Procedures involving joints, such as CMC arthroplasty, are especially painful\textsuperscript{50,51}.

4. Older patients typically consume opioids less than younger patients.\textsuperscript{5,7,34,39,43}

5. Multimodal analgesia strategies result in less opioid use.\textsuperscript{52,53}

6. Preoperative counseling has decreased voluntary opioid use while maintaining high pain management satisfaction.\textsuperscript{37–39}

Additional supplemental findings for each procedure category are included. Oxycodone 5 mg was considered the standard reference dose, with equivalent doses including hydromorphone 2 mg, morphine immediate release 7.5 mg, and oxycodone elixir 1 mg/ml.\textsuperscript{40}

**Recommendations**

**Multimodal anesthesia**

The existing literature on nonopioid multimodal anesthesia strategies and opioid requirements for common upper-extremity procedures organized by anatomic location and tissue type has been presented thus far. We recommend a multimodal anesthesia strategy for all upper-extremity procedures, regardless of type (Table 5). This includes using NSAIDs and acetaminophen after surgery (unless medically contraindicated). A concomitant proton pump inhibitor, such as omeprazole 20 mg twice a day or
Gabapentin is considered less potent than pregabalin, but it has a generic formulary, so it is more cost-effective. Side effects are more pronounced in elderly and renal-impaired patients. The duration of treatment is variable in the literature and ranges from a single postoperative dose to 30 days of treatment.55,56 Further controlled studies are necessary before definitive recommendations can be made. Early evidence is promising that these medications may play a role in upper-extremity surgeons’ analgesic armamentarium, particularly for nerve-related surgeries (ie, carpal tunnel or cubital tunnel syndrome), more painful surgeries, and chronic opioid-consuming patients. Multimodal recommendations are summarized in Table 5.

Recent studies have been of interest in oral anticonvulsant medications, gabapentin and pregabalin, as part of perioperative analgesia. Gabapentin was US Food and Drug Administration-approved in 1994 for the adjunctive treatment of seizure disorders.54 Pregabalin earned US Food and Drug Administration approval in 2004 for treating partial onset seizures, diabetic neuropathy, postherpetic neuralgia, and later in 2007, for fibromyalgia.54 Both medications target the z2δ subunit of N-type voltage-gated calcium channels on dorsal root ganglia and spinal cord neurons. Binding suppresses the release of neurotransmitters similar to substance P, which then reduces neuronal excitability. There have been no high-quality studies in hand surgery examining these medications. However, some promising off-label evidence was shown in lumbar spine surgery, shoulder surgery, and adult reconstruction.55,56 Gabapentin is considered less potent than pregabalin, but it has a generic formulary, so it is more cost-effective. Side effects are more pronounced in elderly and renal-impaired patients. The duration of treatment is variable in the literature and ranges from a single postoperative dose to 30 days of treatment.55,56 Further controlled studies are necessary before definitive recommendations can be made. Early evidence is promising that these medications may play a role in upper-extremity surgeons’ analgesic armamentarium, particularly for nerve-related surgeries (ie, carpal tunnel or cubital tunnel syndrome), more painful surgeries, and chronic opioid-consuming patients. Multimodal recommendations are summarized in Table 5.

Table 1
Hand/Wrist Soft Tissue Procedure Opioid Requirements

| Author                  | Journal               | Level of Evidence | Year | Procedure (N Patients)                      | Opioid Requirement | Comments                  |
|-------------------------|-----------------------|-------------------|------|---------------------------------------------|--------------------|---------------------------|
| Rodgers et al16         | J Hand Surg Am        | I                 | 2012 | CTR, ganglion & mass excision, TFR, tendon/nerve repair (156) | 9 pills (<2 d)     | —                         |
| Stepan et al19          | J Hand Surg Am        | II                | 2018 | CTR, TFR, DQR (123)                         | 4–10 pills/25 MME | —                         |
| Adalbert and Ilyas50    | Hand (N Y)            | II                | 2021 | 1. Soft tissue 2. Hand 3. Wrist procedures (185) CTR (277) | 4.3 pills (median 3.2) | Soft tissue procedures used no opioids in 44% of cases. |
| Chapman et al58         | Hand (N Y)            | II                | 2017 | CTR (56)                                   | >50% used <2 tablets over 2 d (range 0–7 d) | Fewer pills required with age and male sex |
| Peters et al60          | J Hand Surg Am        | IV                | 2018 | CTR (56)                                   | 1. WALANT: 3.85 pills (range 0–32, SD 6.7) 2. MAC: 3.95 pills (range 0–33, SD 5.7) | No difference in opioid use by procedure or anesthesia type. |
| Miller et al11          | Hand                  | II                | 2017 | 1. TFR (78) or CTR (103) with WALANT 2. TFR (50) or CTR (185) with MAC | 1. TFR & MAC: 3.85 pills | Reduced overall opioid use with tramadol. |
| Miller et al66          | Hand                  | II                | 2017 | CTR with postoperative 1. Tamadol (110) or 2. Oxycodone (159) | 1. Tamadol: 3.3 pills for 1.8 d 2. Oxycodone: 4.9 pills for 2.3 d | Authors recommended <10 opioid pills for hand/wrist soft tissue procedures. |
| Kim et al69             | J Bone Joint Surg Am  | II                | 2016 | 1. Soft tissue (904) 2. Hand (593) 3. Wrist (658) 4. CTR (380) 5. TFR (155) 6. Mass excision (95) | 1. 7.4 pills in 2.9 d 2. 7.7 pills in 2.9 d 3. 7.5 pills in 3.5 d 4. 4.2 pills 5. 3.8 pills 6. 4.7 pills | Results based on survey of surgeons not actual patient use. |
| Dwyer et al64           | J Hand Surg Am        | II                | 2018 | CTR (121)                                  | 3 pills (range 0–20) + 11 OTC pills (range 0–20) | Authors recommended 5–10 opioid pills after CTR. |
| Gaspar et al77          | J Bone Joint Surg Am  | II                | 2018 | 1. CTR 2. TFR (266 surveyed attendings) | 1. 112.7 MME (95% CI 101.3–124.1) 2. 100.2 MME (95% CI 90.8–110.0) | Pain scores equivalent for oxycodone, ibuprofen, Tylenol |
| Ilyas et al64           | Orthopedics           | II                | 2019 | CTR (112)/TFR (76)                         | <5–10 pills        | Pain scores equivalent for oxycodone, ibuprofen, Tylenol |

Table 2
Elbow/Forearm Soft Tissue Procedure Opioid Requirements

| Author                  | Journal               | Level of Evidence | Year | Procedure (N Patients)                      | Opioid Requirement | Comments                  |
|-------------------------|-----------------------|-------------------|------|---------------------------------------------|--------------------|---------------------------|
| Kim et al7              | J Bone Joint Surg Am  | II                | 2016 | 1. Soft tissue (904) 2. Elbow & forearm (141) 3. Tendon repair (28) | 1. 7.4 pills in 2.9 d 2. 11.1 pills in 4 d 3. 14.5 pills | Recommend <22.5 MME; more for youth, self-pay, Medicaid, Worker’s compensation. |
| Hozack et al77          | Hand (N y)            | II                | 2019 | 1. Cubital tunnel procedures (100) 2. CuTR (76) 3. UNT (24) | 1. 150 MME (range 0–300) 2. 40.4 MME (5.4 pills) 3. 625 MME (8.3 pills) | Medicare < private insured & worker’s compensation. Older patients consumed less. |

CTR, carpal tunnel release; DQR, de Quervain release; MAC, monitored anesthesia care; OTC, over-the-counter; TFR, trigger finger release; WALANT, Wide awake, local anesthesia, no tourniquet.
Soft tissue procedures

Opioids should be routinely prescribed on a PRN basis for breakthrough pain above standing acetaminophen and NSAID prescription. For soft tissue procedures of the hand and wrist, a maximum of 30 MME per day (equivalent to 4 doses of 5 mg oxycodone tablets per day) for postoperative analgesia is indicated, with a maximum prescription of 5 tablets at a time (Table 6). For soft tissue procedures of the forearm and elbow, a maximum of 50 MME per day (equivalent to 7 doses of 5 mg oxycodone tablets per day) for postoperative analgesia, with a maximum prescription of 10 tablets at a time (Table 6). Smaller initial prescription amounts...
are recommended to avoid inadvertent overprescribing and diversion. Furthermore, this is the maximum-recommended amount, as lower quantities are typically sufficient, especially for older and/or male patients.9,57,58 Soft tissue procedures with small incisions, superficial and limited dissection, and no implant placement (such as skin excisions and trigger finger release), generally require no opioids after surgery.

**Bony procedures**

For bony procedures of the hand, wrist, forearm, and elbow, a maximum prescription of 50 MME per day (equivalent to 7 doses of 5 mg oxycodone tablets per day) for postoperative analgesia is indicated, with a maximum prescription of 10–20 tablets (Table 6). Smaller initial prescription amounts are recommended to avoid inadvertent overprescribing and diversion. Moreover, refill requests are desirable in lieu of overprescribing initially. Furthermore, this is the maximum-recommended amount; lower quantities are typically sufficient, especially for older and/or male patients.9,57,58

Opioid stewardship by hand surgeons can substantively combat the US opioid epidemic. Appropriate opioid dosing and postoperative multimodal analgesic strategies are more imperative than ever with the coronavirus disease 2019 pandemic, leading to increased opioid overdoses. This review offers comprehensive, evidence-based, easy-to-follow analgesic regimens and opioid dosages for common hand and upper-extremity surgeries.

**References**

1. Centers for Disease Control and Prevention. CDC Wide-ranging Online Data for Epidemiologic Research. National Center for Health Statistics. Published 2020. Accessed July 16, 2021 http://wonder.cdc.gov

2. Mattson CL, Tanz LJ, Quinn K, Karina M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202–207.

3. Guy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697–704.

4. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and misuse of opioids: a ten-year perspective. Pain Physician. 2010;13(5):401–435.

5. Kaafarani HMA, Han K, El-Mohb M, et al. Opioids after surgery in the United States versus the rest of the world: the international patterns of opioid prescribing (ipop) multicenter study. Ann Surg. 2020;272(6):879–886.

6. Wolf Administration Highlights Opioid Response Efforts as Opioid Crisis Continues to Affect Pennsylvania [press release]. Pennsylvania Commonwealth Pressroom, 1/26/2021 2021. Accessed April 21, 2022. Available at: https://www.media.pa.gov/pages/health-details.aspx?newsid=1269

7. Hozack BA, Rivlin M, Graham J, Lutsky KB, Beredjiklian PK. Validation of the prescription drug monitoring program Web site. J Opioid Manag. 2015;11(6):495–498.

8. Stepan JG, Sacks HA, Verret CJ, Wessel LE, Kumar K, Fufa DT. Standardized perioperative patient education decreases opioid use after hand surgery: a randomized controlled trial. Plast Reconstr Surg. 2021;147(2):409–418.

9. Kim N, Matzon JJ, Abbo J, et al. A prospective evaluation of opioid utilization after upper-extremity surgical procedures: identifying consumption patterns and determining prescribing guidelines. J Bone Joint Surg Am. 2016;98(20):e89.

10. Labrum JT, Ilyas AM. The opioid epidemic: postoperative pain management strategies in orthopaedics. J Bone Joint Surg Am. 2017;99(5):e14.

11. (SAMSHA) SAaMHSA. National Survey on Drug Use and Health (NSDUH). 2020. Accessed April 21, 2022. Available at: https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health

12. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes—United States Surveillance Special Report. U.S. Department of Health and Human Services;2018. Accessed April 21, 2022. https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf

13. Haley DF, Saizt R. The opioid epidemic during the COVID-19 pandemic. JAMA. 2020;324(16):1615–1617.

14. Silva MJ, Kelly Z. The escalation of the opioid epidemic due to COVID-19 and resulting lessons about treatment approaches. J Manag Care Spec Pharm. 2020;26(7):e202–e204.

15. Becker WC, Fieflin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Am J Intern Med. 2020;173(1):59–60.

16. Rodrigs J, Cunningham K, Fitzgerald K, Finnerty E. Opioid consumption following outpatient upper extremity surgery. J Hand Surg Am. 2013;37(4):645–650.

17. Leopold SS, Beadling L. Editorial: the opioid epidemic and orthopaedic surgery—no pain, who gains? Clin Orthop Relat Res. 2017;475(10):2351–2354.

18. Menendez ME, Ring D, Bateman TE. Preoperative opioid misuse is associated with increased morbidity and mortality after elective orthopaedic surgery. Clin Orthop Relat Res. 2017;475(7):2402–2412.

19. Farley KK, Fakunle OP, Spencer SC, Gottschalk MB, Wagner ER. The association of preoperative opioid use with revision surgery and complications following carpal tunnel arthroplasty. J Hand Surg Am. 2021;46(11):1025.e1–1025.e14.

20. Farley KK, Wilson JM, Spencer SC, et al. Preoperative opioid use is a risk factor for revision surgery, complications, and increased resource utilization after arthroscopic rotator cuff repair. J Am Sports Med. 2020;48(13):3339–3346.

21. Creditor HGV, Massel DH, Barera CM, Ezzuddin NS, Emerson CP, Jose J. Systemic complications and radiographic findings of opioid use and misuse: an overview for orthopedic surgeons. J Hand Surg Am. 2019;45(1):76–83.

22. Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014;112(6):991–1004.

23. Adams AJP, Paladino J, Townsend C, Ilyas AM. Preoperative opioid use results in greater postoperative opioid consumption after thumb basal joint arthroplasty. J Hand Surg Glob Open. 2022;4(2):78–83.

24. Caspar MP, Pliego EM, Adams AJ, et al. Self-reported postoperative opioid-prescribing practices following commonly performed orthopaedic hand and wrist surgical procedures: a nationwide survey comparing attending surgeons and trainees. J Bone Joint Surg Am. 2018;100(19):e127.

25. Delgado CN, Youssif SA, Sadhu A, Shipp MM, Sanghavi KK, Giladi AM. Variation in postoperative opioid prescribing among upper-extremity surgery providers. J Hand Surg Glob Open. 2021;3(1):17–23.

26. Stepan JG, Sacks HA, Lovecchio FC, et al. Opioid prescriber education and guidelines for ambulatory upper-extremity surgery: evaluation of an institutional protocol. J Hand Surg Am. 2019;44(2):129–136.
30. Stanek JJ, Renslow MA, Kallainen LC. The effect of an educational program on opioid prescription patterns in hand surgery: a quality improvement program. J Hand Surg Am. 2015;40(2):341–346.

31. Shah KN, Reid DBC, Ruddell JH, et al. Is opioid-limiting legislation effective for hand surgery patients? Hand (N Y). 2021;158944720988132.

32. Pennsylvania Orthopaedic Society. Opioid Recommendations for Acute Pain. Pennsylvania Orthopaedic Society; 2020. Accessed April 21, 2022. https://www.paosociety.org/assets/docs/POS%20Opioid%20Statement%20and%20Recommendations%20Final.pdf

33. Ilyas AM, Chapman T, Zmistowski B, Sandrowski K, Graham J, Hammoud S. The effect of standardized perioperative patient education on opioid use after minor soft tissue procedures distal to the wrist. J Hand Surg Am. 2021;46(1):580.e9.

34. Gauger EM, Gauger EJ, Desai MJ, Lee DH. Opioid use after upper extremity trauma. J Bone Joint Surg Am. 2018;100(14):e1155.

35. Qiu MM, Qiu CD, Shah CM. Risk factors for prolonged opioid use after open treatment of distal radius fractures. Hand (N Y). 2019;11(4):452–455.

36. Abouk R, Powell D. Can electronic prescribing mandates reduce opioid-related overdoses? Econ Hum Biol. 2021;42:101000.

37. Ilyas AM, Chapman T, Zmistowski B, Sandrowski K, Graham J, Hammoud S. The effect of preoperative opioid education on opioid consumption after outpatient orthopedic surgery: a prospective randomized trial. Orthopedics. 2021;44(2):122–127.

38. Alter TH, Sandrowski K, Gallant G, Kwok M, Ilyas AM. Complications of volar plating of distal radius fractures: a systematic review. J Wrist Surg. 2019;8(3):255–262.

39. Vincent S, Paskey T, Critchlow E, et al. Prospective randomized study examining preoperative opioid counseling on postoperative opioid consumption after upper extremity surgery. Hand (N Y). 2022;17(2):200–205.

40. American Society for Surgery of the Hand. Opioid Resources. ASSH. Published 2021. Accessed July 30, 2021. https://www.assh.org/s/opioid-resources

41. Zohar-Bondar A, Stepan JG, Chapman T, Sacks H, Verrett I, Fufa DT. The effect of Helmerhorst GT, Vranceanu AM, Vrahas M, Smith M, Ring D. Risk factors for Dart RC, Iwanicki JL, Black JC, Olsen HA, Severtson SG. Measuring prescription consumption after upper extremity surgery. J Hand Surg Am. 2021;16(4):491–497.

42. Harrison RK, DiMeo T, Klieweiter RD, Ruff ME, Awan HM. Multimodal pain control in ambulatory hand surgery. Am J Orthop (Belle Mead NJ). 2018;47(6):e241.

43. Neumeister EL, Beason AM, Thayer JA, El Bitar Y. Perioperative pain management in hand and upper extremity surgery. Clin Plast Surg. 2020;47(2):323–334.

44. Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoids. JAMA Intern Med. 2019;179(5):695–701.

45. Schmidt PC, Ruchelli G, Mackey SC, Carroll IR. Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology. 2013;119(5):1215–1221.

46. Brunton LM, Laporte DM. Use of gabapentin and pregabalin for hand surgery patients. J Hand Surg Am. 2012;37(7):1486–1488.

47. Hozack BA, Abboudi J, Gallant G, et al. Prospective evaluation of opioid consumption following cubital tunnel decompression surgery. Hand (N Y). 2019;14(1):42–47.

48. Chapman T, Kim N, Maitlenfort M, Ilyas AM. Prospective evaluation of opioid consumption following carpal tunnel release surgery. Hand (N Y). 2017;12(1):39–42.

49. Stepan JC, London DA, Osei DA, Boyer ML, Dardas AZ, Calfee RP. Perioperative celecoxib and postoperative opioid use in hand surgery: a prospective cohort study. J Hand Surg Am. 2018;43(4):346–353.

50. Peters B, Izdapanah A, Islur A. Analgesic consumption following outpatient carpal tunnel release. J Hand Surg Am. 2018;43(2):189.e1–189.e5.

51. Miller A, Kim N, Ilyas AM. Prospective evaluation of opioid consumption following carpal tunnel release surgery. Hand (N Y). 2017;12(6):606–609.

52. Miller A, Kim N, Zmistowski B, Ilyas AM, Matzohn J. Postoperative pain management following carpal tunnel release: a prospective cohort evaluation. Hand (N Y). 2017;12(6):541–545.

53. Dwyer CL, Soong M, Hunter A, Dashe J, Tolo E, Kasparyan NG. Prospective evaluation of an opioid reduction protocol in hand surgery. J Hand Surg Am. 2018;43(6):516–522.e1.

54. Ilyas AM, Miller AJ, Graham JG, Matzohn J. A prospective, randomized, double-blinded trial comparing acetaminophen, ibuprofen, and oxycodone for pain management after hand surgery. Orthopedics. 2019;42(2):110–115.

55. O’Neil JT, Wang ML, Kim N, Maitlenfort M, Ilyas AM. Prospective evaluation of opioid consumption after distal radius fracture repair surgery. Am J Orthop (Belle Mead NJ). 2017;46(1):E35–E40.

56. Cunningham DJ, LaRose MA, Anakwenze OA, et al. Fracture location impacts opioid demand in upper extremity fracture surgery. Injury. 2021;52(8):2314–2321.

57. Bhashyam AR, Basilico M, Weaver MJ, Harris MB, Heng M. Using historical variation in opioid prescribing immediately after fracture surgery to guide maximum initial prescriptions. J Orthop Trauma. 2019;33(4):e131–e136.